BeyondSpring (BYSI) vs Seres Therapeutics (MCRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BeyondSpring is the larger company by market cap ($13.7 million vs $12.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BYSI | MCRB |
|---|---|---|
| Share price | $0.33 | $1.24 |
| Market cap | $13.66M | $12.64M |
| 1-day change | -24.49% | -6.77% |
| YTD return | -79.75% | — |
| 1-year return | -82.77% | — |
| 5-year return | -97.70% | — |
| EPS (TTM) | $-0.20 | $-5.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $789.00K |
| Net income (latest FY) | $-1.01M | $5.70M |
| Operating margin | — | -11910.14% |
| Net margin | — | 721.93% |
| 52-week high | $2.44 | $18.86 |
| 52-week low | $0.299 | $1.20 |
| Distance from 52-week high | -86.48% | -93.43% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1270.97% |
| Average volume | 261.79K | 74.83K |
| Shares outstanding | 41.41M | 10.20M |
| Employees | 44 | 66 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BeyondSpring
BYSI stock →BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
About Seres Therapeutics
MCRB stock →Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees
BYSI vs MCRB FAQ
Which is bigger, BeyondSpring or Seres Therapeutics?
BeyondSpring (BYSI) is larger, with a market capitalization of $13.66M compared with $12.64M for Seres Therapeutics (MCRB).
Are BeyondSpring and Seres Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.